Sulforaphane from Cruciferous Vegetables: Recent Advances to Improve Glioblastoma Treatment.

Giulia Sita, Patrizia Hrelia, Agnese Graziosi, Fabiana Morroni

Journal: Nutrients 2019;10(11):1755

PMID: 30441761

Abstract

Sulforaphane (SFN), an isothiocyanate (ITC) derived from cruciferous vegetables, particularly broccoli and broccoli sprouts, has been widely investigated due to its promising health-promoting properties in disease, and low toxicity in normal tissue. Although not yet fully understood, many mechanisms of anticancer activity at each step of cancer development have been attributed to this ITC. Given the promising data available regarding SFN, this review aimed to provide an overview on the potential activities of SFN related to the cellular mechanisms involved in glioblastoma (GBM) progression. GBM is the most frequent malignant brain tumor among adults and is currently an incurable disease due mostly to its highly invasive phenotype, and the poor efficacy of the available therapies. Despite all efforts, the median overall survival of GBM patients remains approximately 1.5 years under therapy. Therefore, there is an urgent need to provide support for translating the progress in understanding the molecular background of GBM into more complex, but promising therapeutic strategies, in which SFN may find a leading role.

Address: Department of Pharmacy and BioTechnology, Alma Mater Studiorum-University of Bologna, via Irnerio 48, 40126 Bologna, Italy. [email protected].; Department of Pharmacy and BioTechnology, Alma Mater Studiorum-University of Bologna, via Irnerio 48, 40126 Bologna, Italy. [email protected].; Department of Pharmacy and BioTechnology, Alma Mater Studiorum-University of Bologna, via Irnerio 48, 40126 Bologna, Italy. [email protected].; Department of Pharmacy and BioTechnology, Alma Mater Studiorum-University of Bologna, via Irnerio 48, 40126 Bologna, Italy. [email protected].
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.